Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,881 to 1,900 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spatial and temporal roles of SARS-CoV PLpro -A snapshot. | FASEB J | 2021 | 33368679 | PubTator, text mining | PubMed |
| Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing. | Biochem Biophys Rep | 2021 | 33364445 | PubTator, text mining | PubMed |
| A Ligand Selection Strategy Identifies Chemical Probes Targeting the Proteases of SARS-CoV-2. | Angew Chem Int Ed Engl | 2021 | 33350010 | PubTator, text mining | PubMed |
| Structure of the multiple functional domains from coronavirus nonstructural protein 3. | Emerg Microbes Infect | 2021 | 33327866 | PubTator, text mining | PubMed |
| Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19. | Curr Res Struct Biol | 2021 | 33319212 | PubTator, text mining | PubMed |
| Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics. | Gene Ther | 2021 | 33318646 | PubTator, text mining | PubMed |
| Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. | Adv Drug Deliv Rev | 2021 | 33316346 | PubTator, text mining | PubMed |
| Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs. | Int J Biol Macromol | 2021 | 33309661 | PubTator, text mining | PubMed |
| The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. | Int Immunopharmacol | 2021 | 33302033 | PubTator, text mining | PubMed |
| SARS-CoV-2: Targeted managements and vaccine development. | Cytokine Growth Factor Rev | 2021 | 33293238 | PubTator, text mining | PubMed |
| The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2. | Biochem Biophys Res Commun | 2021 | 33288200 | PubTator, text mining | PubMed |
| A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*. | ChemMedChem | 2021 | 33283984 | PubTator, text mining | PubMed |
| Genomic analysis of group A rotavirus G12P[8] including a new Japanese strain revealed evidence for intergenotypic recombination in VP7 and VP4 genes. | Infect Genet Evol | 2021 | 33278636 | PubTator, text mining | PubMed |
| Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. | Med Res Rev | 2021 | 33277927 | PubTator, text mining | PubMed |
| 1H, 13C, and 15N backbone chemical shift assignments of the C-terminal dimerization domain of SARS-CoV-2 nucleocapsid protein. | Biomol NMR Assign | 2021 | 33270159 | PubTator, text mining | PubMed |
| The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection. | J Mol Med (Berl) | 2021 | 33269412 | PubTator, text mining | PubMed |
| A Versatile Reporter System To Monitor Virus-Infected Cells and Its Application to Dengue Virus and SARS-CoV-2. | J Virol | 2021 | 33257477 | PubTator, text mining | PubMed |
| Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. | Biomed Pharmacother | 2021 | 33254013 | PubTator, text mining | PubMed |
| Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update. | Food Chem Toxicol | 2021 | 33253764 | PubTator, text mining | PubMed |
| One year update on the COVID-19 pandemic: Where are we now? | Acta Trop | 2021 | 33253656 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=95